Dr. Barratt’s research is focussed on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. He is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and Convener of the International IgA Nephropathy Network.  He works closely with pharmaceutical companies interested in new treatments for IgA nephropathy, and is Chief Investigator for a number of international randomised controlled Phase 2 and 3 clinical trials in IgA nephropathy. He is co-Chair of the UK Glomerulonephritis Clinical Study Group and the IgA nephropathy lead for the KDIGO Clinical Practice Guidelines for Glomerular Diseases.